United Health Products (UHP) is a pre-revenue, development-stage medical device company built around a single product: CelluSTAT, a hemostatic gauze made from chemically treated cotton cellulose. CelluSTAT is placed on a wound or surgical incision, where it converts to a gel on contact with blood to stop bleeding. UHP already holds FDA 510(k) clearance for superficial wound care, but has paused commercial activity to pursue FDA Premarket Approval (PMA) for the more valuable Class III human surgical market, where fewer approved competitors support higher pricing. A 2019 clinical trial in 232 patients showed CelluSTAT was statistically superior to Ethicon's Surgicel Original in time to hemostasis. However, the FDA issued a Warning Letter in March 2025 citing five violations related to how that trial was conducted, and UHP cannot proceed with a supplemental clinical study until those issues are resolved — a remediation process expected to run through at least July 2026. UHP's business model is not to commercialize independently. If PMA approval is obtained, UHP intends to sell, merge with, or partner with an established surgical device company. UHP operates with just two full-time consulting personnel, spends modestly on R&D, and funds operations through a dilutive equity line and convertible debt. Patent protection on the underlying technology runs through 2029, creating some urgency around the regulatory timeline. Any return to investors depends entirely on resolving the FDA Warning Letter, obtaining PMA approval, and completing a successful M&A or partnership transaction — none of which are assured.